Skip to main content

Table 2 Estimated mean difference in 1- and 3-year change from baseline on composite Z score for the three intervention groups compared to the placebo group

From: Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial

Groups

Estimated mean change from baseline (95% CI)

Estimated mean between-group difference in change from baseline (95% CI)

Unadjusted

Adjusteda

vs. placebo

Raw P

Hochberg P

vs. placebo

Raw P

Hochberg P

1-year ITT MAPT analysis (n = 483)

Positive plasma Aβ42/40

  Multidomain plus omega 3

0.1392 (0.0018; 0.2765)

0.1917 (0.0136; 0.3699)

0.0350

0.1049

0.1891 (0.0104; 0.3679)

0.0381

0.1144

  Omega 3 alone

-0.0267 (-0.1555; 0.1022)

0.0259 (-0.1458; 0.1976)

0.7669

0.7669

0.0074 (-0.1676; 0.1824)

0.9338

0.9338

  Multidomain plus placebo

0.0835 (-0.0490; 0.2160)

0.1361 (-0.0383; 0.3106)

0.1260

0.2519

0.1113 (-0.0649; 0.2874)

0.2153

0.4306

  Placebo

-0.0526 (-0.1661; 0.0609)

-

-

-

-

-

-

Negative plasma Aβ42/40

  Multidomain plus omega 3

-0.0059 (-0.0884; 0.0765)

0.0241 (-0.1007; 0.1488)

0.7050

0.9950

0.0199 (-0.1066; 0.1463)

0.7578

0.9306

  Omega 3 alone

-0.0296 (-0.1240; 0.0648)

0.0004 (-0.1325; 0.1334)

0.9950

0.9950

0.0135 (-0.1584; 0.1879)

0.8445

0.9306

  Multidomain plus placebo

-0.0176 (-0.1058; 0.0707)

0.0124 (-0.1162; 0.1411)

0.8494

0.9950

0.0058 (-0.1244; 0.1360)

0.9306

0.9306

  Placebo

-0.0300 (-0.1236; 0.0636)

-

-

-

-

-

-

1-year per-protocol MAPT analysis (n = 457)

Positive plasma Aβ42/40

  Multidomain plus omega 3

0.1880 (0.0440; 0.3319)

0.2435 (0.0582; 0.4287)

0.0101

0.0302

0.2424 (0.0571; 0.4276)

0.0104

0.0313

  Omega 3 alone

-0.0264 (-0.1564; 0.1036)

0.0291 (-0.1455; 0.2037)

0.7437

0.7437

0.0070 (-0.1705; 0.1845)

0.9383

0.9383

  Multidomain plus placebo

0.0846 (-0.0527; 0.2220)

0.1402 (-0.0400; 0.3203)

0.1270

0.2540

0.1132 (-0.0684; 0.2949)

0.2214

0.4428

  Placebo

-0.0555 (-0.1721; 0.0611)

-

-

-

-

-

-

Negative plasma Aβ42/40

  Multidomain plus omega 3

-0.0022 (-0.0894; 0.0850)

0.0288 (-0.1002; 0.1578)

0.6611

0.8971

0.0229 (-0.1073; 0.1532)

0.7298

0.9902

  Omega 3 alone

-0.0399 (-0.1363; 0.0565)

-0.0089 (-0.1443; 0.1265)

0.8971

0.8971

-0.0009 (-0.1375; 0.1358)

0.9902

0.9902

  Multidomain plus placebo

-0.0115 (-0.1046; 0.0816)

0.0195 (-0.1136; 0.1526)

0.7735

0.8971

0.0178 (-0.1165; 0.1522)

0.7947

0.9902

  Placebo

-0.0310 (0.1261; 0.0641)

-

-

-

-

-

-

3-year ITT MAPT analysis (n = 483)

Positive plasma Aβ42/40

  Multidomain plus omega 3

-0.0931 (-0.2959; 0.1098)

0.2818 (0.0190; 0.5446)

0.0357

0.1071

0.3030 (0.0420; 0.5640)

0.0230

0.0690

  Omega 3 alone

-0.2530 (-0.4443; -0.0616)

0.1219 (-0.1322; 0.3760)

0.3461

0.3461

0.1257 (-0.1305; 0.3820)

0.3353

0.3353

  Multidomain plus placebo

-0.2051 (-0.3972; -0.0130)

0.1698 (-0.0849; 0.4244)

0.1907

0.3461

0.1399 (-0.1148; 0.3946)

0.2808

0.3353

  Placebo

-0.3749 (-0.5420; -0.2077)

-

-

-

-

-

-

Negative plasma Aβ42/40

  Multidomain plus omega 3

-0.1527 (-0.2729; -0.0325)

-0.0075 (-0.1890; 0.1740)

0.9352

0.9352

-0.0037 (-0.1861; 0.1787)

0.9684

0.9684

  Omega 3 alone

-0.1173 (-0.2550; 0.0203)

0.0278 (-0.1657; 0.2213)

0.7775

0.9352

0.0194 (-0.1748; 0.2136)

0.8443

0.9684

  Multidomain plus placebo

-0.1356 (-0.2663; -0.0049)

0.0096 (-0.1791; 0.1982)

0.9206

0.9352

0.0180 (-0.1710; 0.2071)

0.8512

0.9684

  Placebo

-0.1452 (-0.2812; -0.0091)

-

-

-

-

-

-

3-year per-protocol MAPT analysis (n = 457)

Positive plasma Aβ42/40

  Multidomain plus omega 3

-0.0298 (-0.2415; 0.1820)

0.3490 (0.0769; 0.6210)

0.0121

0.0362

0.3747 (0.1055; 0.6439)

0.0065

0.0195

  Omega 3 alone

-0.2534 (-0.4461; -0.0607)

0.1253 (-0.1322; 0.3828)

0.3392

0.3392

0.1254 (-0.1334; 0.3842)

0.3413

0.3413

  Multidomain plus placebo

-0.2158 (-0.4142; -0.0173)

0.1630 (-0.0988; 0.4248)

0.2217

0.3392

0.1297 (-0.1317; 0.3911)

0.3299

0.3413

  Placebo

-0.3787 (-0.5495; -0.2080)

-

-

-

-

-

-

Negative plasma Aβ42/40

  Multidomain plus omega 3

-0.1452 (-0.2725; -0.0179)

0.0047 (-0.1830; 0.1924)

0.9605

0.9605

0.0051 (-0.1827; 0.1930)

0.9572

0.9572

  Omega 3 alone

-0.1284 (-0.2683; 0.0116)

0.0216 (-0.1750; 0.2181)

0.8294

0.9605

0.0068 (-0.1897; 0.2033)

0.9457

0.9572

  Multidomain plus placebo

-0.1321 (-0.2694; 0.0051)

0.0178 (-0.1768; 0.2123)

0.8576

0.9605

0.0289 (-0.1656; 0.2234)

0.7703

0.9572

  Placebo

-0.1499 (-0.2878; -0.0120)

-

-

-

-

-

-

  1. ITT intention-to-treat, MAPT Multidomain Alzheimer Prevention Trial
  2. aAnalysis adjusted for age, sex, level of education, APOE ε4 genotype, and clinical dementia rating global score